Meeting
2021 ASCO Annual Meeting
Cisplatin and capecitabine induction chemotherapy in nasopharyngeal carcinoma.
Authors
Zhiyuan Xu
Department of Clinical Oncology,The University of Hong Kong-Shenzhen Hospital,Shenzhen,China, Shenzhen, China
Zhiyuan Xu , Li Yang , Victor Ho-Fun Lee , Anne W. M. Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT03427359
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6065)
DOI
10.1200/JCO.2021.39.15_suppl.6065
Abstract #
6065
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Induction chemotherapy (CT) with docetaxel, cisplatin, and fluorouracil (TPF) followed by concomitant cisplatin plus radiotherapy in locally advanced nasopharyngeal cancer (NPC): Results after 06 years.
First Author: Esma Kerboua
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.
First Author: Michele Reni
Poster
2022 ASCO Annual Meeting
Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage TanyN3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial.
First Author: Hu Liang
Poster
2020 ASCO Virtual Scientific Program
X versus XELOX versus PF in definitive concurrent chemoradiotherapy (DCRT) for local advanced squamous esophageal cancer (ESCC): Update from a multicenter, open-label, randomized III trial, CRTCOESC trial.
First Author: Ruinuo Jia